You may also be interested in...
Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.
A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.
India’s Granules has grown through increased market penetration of its existing products as well as new product launches. The company is planning to invest in expanding its API capacity, finished dosages and a new multiple unit pellet facility.